Compare SPT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPT | EVO |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.6M | 1.1B |
| IPO Year | 2019 | N/A |
| Metric | SPT | EVO |
|---|---|---|
| Price | $7.49 | $3.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $11.75 | $7.00 |
| AVG Volume (30 Days) | ★ 1.4M | 47.1K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $457,547,000.00 | N/A |
| Revenue This Year | $8.86 | $1.37 |
| Revenue Next Year | $8.04 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.72 | N/A |
| 52 Week Low | $4.92 | $2.31 |
| 52 Week High | $22.59 | $4.42 |
| Indicator | SPT | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 65.40 | 56.03 |
| Support Level | $5.94 | $2.88 |
| Resistance Level | $11.50 | $3.75 |
| Average True Range (ATR) | 0.41 | 0.07 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 98.06 | 89.58 |
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.